jobs page link image
follow us on facebook follow us on twitter
00  Month

Second booster jabs on way for over-75s

Created on 12/03/2022 @ 09:37

A fresh vaccination programme providing a second booster is set to be launched in Powys this spring, but only targeting the over 75s and the most vulnerable.

The announcement came amidst news that more than 125,000 vaccines have been administered at the Newtown centre, which has now moved to Park Street Day Centre from Maldwyn Leisure Centre.

With the second anniversary approaching of the first lockdown on March 23, 2020, Powys Teaching Health Board said that the spring booster programme will target the over 75s, residents of care homes for older adults, and people aged 12+ with severe immunosuppression. And there could be a further booster programme in the autumn for the rest of us too.

“Looking ahead it is clear that vaccination will continue to be a critical part of our response to Coronavirus,” said Adrian Osborne, Programme Director (COVID-19 Vaccination and TTP), adding that invitations will go out soon for April appointments. A reserve list is already open at here.

“A spring booster programme is just about to get under way, the offer of vaccination is now open to all 5-11 year olds, and drop-in opportunities remain available for people who have not yet taken up the offer.

“And the Joint Committee on Vaccination and Immunisation has already indicated that there will be an autumn vaccination programme. We expect this will become an annual event to maintain high levels of immunity and help protect against new Coronavirus variants.”

The latest vaccination figures in Powys:

  • 91.6% of adults have taken up their first dose, 89.6% have completed their primary course, and 79.2% have received their booster.
  • 83.6% of 16-17 year olds have taken up their first dose, and 70.2% have received their second dose. Boosters are under way.
  • 66.3% of 12-15 year olds have taken up their first dose, and 44.7% have received their second dose. In this age group boosters are currently only recommended for people in clinical risk groups.